Canaccord Genuity Group Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND) had its target price lifted by stock analysts at Canaccord Genuity Group from $268.00 to $274.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group‘s price objective points to a potential upside of 2.59% from the company’s current price.

Other equities analysts have also issued reports about the company. UBS Group started coverage on Ascendis Pharma A/S in a report on Thursday, October 15th. They set a “buy” rating and a $269.00 target price on the stock. Royal Bank Of Canada upped their price target on Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. BMO Capital Markets reissued an “outperform” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Citigroup cut their price objective on Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Finally, Oppenheimer raised their price objective on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $306.55.

Ascendis Pharma A/S Stock Up 3.0%

Ascendis Pharma A/S stock opened at $267.07 on Friday. The company has a market capitalization of $16.66 billion, a P/E ratio of 20.72 and a beta of 0.40. The firm’s fifty day simple moving average is $242.58 and its 200-day simple moving average is $239.65. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 1-year low of $188.07 and a 1-year high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Sell-side analysts forecast that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 40.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Chicago Partners Investment Group LLC boosted its stake in Ascendis Pharma A/S by 2.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock valued at $564,000 after buying an additional 52 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Ascendis Pharma A/S by 34.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Ascendis Pharma A/S by 48.4% during the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after buying an additional 91 shares in the last quarter. ProShare Advisors LLC boosted its position in Ascendis Pharma A/S by 5.6% in the 3rd quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 113 shares during the last quarter. Finally, AlphaCentric Advisors LLC boosted its position in Ascendis Pharma A/S by 2.6% in the 3rd quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company’s stock valued at $1,072,000 after buying an additional 121 shares during the last quarter.

Ascendis Pharma A/S News Roundup

Investors following ASND have been watching these news items:

• Positive Sentiment: Regulatory progress may add to the growth outlook: European regulators recommended marketing authorization for TransCon CNP, with a European Commission decision expected in Q4 2026 and a planned first launch in Germany in Q1 2027. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.